Opinion

Video

Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Hands holding a crochet heart | Image Credit: © StockerThings - stock.adobe.com
Wooden blocks spelling HDL, LDL | Image Credit: © surasak - stock.adobe.com
Anticoagulant attacking blood clot | Image Credit: © BURIN93 - stock.adobe.com
Depiction of man aging | Image Credit: © Top AI images - stock.adobe.com
Map with pins | Image Credit: © Tryfonov - stock.adobe.com
Related Content
Block letters spelling POTS | Image Credit: © Fauzi - stock.adobe.com
December 3rd 2024

Patients With Post-COVID POTS Experience Disruptions in Circadian Blood Pressure Rhythm Regulation

Alexandra Gerlach, Associate Editor
Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events
December 2nd 2024

Before the Big Event: AI-Enabled Remote Cardiac Monitoring Can Mitigate Stress-Related Cardiovascular Events

Stuart Long
Aprocitentan: A New Hope in Resistant Hypertension Management
November 27th 2024

Aprocitentan: A New Hope in Resistant Hypertension Management

Kamila Dymala, PharmD, RPh, MBA, BCMTM, PACS
Cardiovascular Health, Atrial Fibrillation, FDA Approval | Image Credit: Sebastian Kaulitzki | stock.adobe.com
Published: November 27th 2024 | Updated: November 27th 2024

FDA Approves Landiolol For Treatment of Supraventricular Tachycardia

Ashley Gallagher, Associate Editor
Cardiomyopathy block letters | Image Credit: © lexiconimages - stock.adobe.com
November 25th 2024

Acoramidis Received FDA Approval for Treatment of Transthyretin Amyloid Cardiomyopathy

Alexandra Gerlach, Associate Editor
β-Blockers: Big Role or Shrinking Spotlight in Cardiovascular Therapy?
November 25th 2024

β-Blockers: Big Role or Shrinking Spotlight in Cardiovascular Therapy?

Laney Murff, PharmD/BSPS candidate Ron Welch, PharmD, BCPS, BCIDP